We are an international biotechnology company that is focused in the field of regenerative medicine. We are committed to developing therapeutic products that we believe have best-in-class potential, meaning therapies that have the potential to be safer and more effective than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration.
Our MultiStem® cell therapy, a patented and proprietary allogeneic “off-the-shelf” stem cell product, is our lead platform product and has shown promise for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as certain other critical care conditions. MultiStem is currently being evaluated in several clinical-stage programs. Our most advanced program is focused on the treatment of ischemic stroke, which is being evaluated in a registrational trial in Japan, and in a Phase 3 clinical trial primarily in North America and Europe under a Special Protocol Assessment, or SPA. Our clinical development programs are focused on treating neurological conditions, inflammatory and immune disorders, cardiovascular disease, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients. These represent major areas of clinical need, as well as substantial commercial opportunities.
Source
